GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...

The results further undermine Relvar Ellipta, which is already struggling to establish itself in the COPD market. The drug is positioned as a follow-up product to GSK’s blockbuster Advair ...

The growth of these products comes from strong ... while sales on Revlar/Breo Ellipta were up 5%. Ventolin sales rose 5%. In General Medicines, GSK expects sales to increase in a mid-single ...

A month has gone by since the last earnings report for GSK (GSK). Shares have lost about ... The growth of these products comes from strong patient demand. These two long-acting medicines ...

Teva Pharmaceutical Industries Ltd. ADR-1.87% $19.76B ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...